Leading Core Lab Provides Oncology Expertise and Advanced Technology
Washington, DC—Cardiocore, a premier centralized cardiac testing lab, announced today that it has been selected as a preferred provider by a Top-Ten biotechnology organization. Before choosing Cardiocore, this drug developer reviewed information from more than ten cardiac safety service providers. The primary considerations that led to Cardiocore’s selection included staff expertise, breadth of services, beneficial technologies, project management processes and operational flexibility.
Like many large biotech companies, this sponsor is developing a number of oncology drug candidates with specialized cardiac safety testing requirements. Cardiocore top scientists’ expertise in oncology trials and cardiac testing modalities support the sponsor’s development of advanced cardiac testing protocols. Because of their value in oncology trials, Cardiocore’s centralized echocardiography (ECHO) and multigated acquisition scan (MUGA) services also benefit this sponsor, as a compliment to Cardiocore’s global electrocardiography (ECG) and Holter monitoring offering.
Within the preferred provider relationship, cardiac data are available to the sponsor and authorized investigative sites through the CardioPortal™ system. Many of Cardiocore’s technology-focused clients appreciate this advanced web service for its ease-of-use, quick customization and real time updates.
In addition to the rapid data delivery enabled by Cardiocore’s technologies, this sponsor is also able accelerate its decision-making capabilities as a benefit of Cardiocore’s operational flexibility. In the first clinical trial under the preferred provider agreement, the sponsor requested expedited ECG processing within 24-hours. Cardiocore has provided STAT analyses by board-certified cardiologists that are immediately available to the sponsor and originating clinical sites through any web browser, accessing the secured CardioPortal.
Cardiocore Chief Executive Officer, Jennifer Cotteleer said, “We are proud to earn this preferred provider award from another leading biotechnology organization.” She added, “We appreciate this client’s interest in expertise and innovation, and we look forward to many years of providing them the best quality scientific consulting, global cardiac testing services and customized data management.”
About Cardiocore: Cardiocore has provided superior centralized cardiac testing services to the pharmaceutical industry for 17 years. Services include centralized electrocardiography (ECG), Holter monitoring, echocardiography (ECHO), multigated acquisition scans (MUGA), protocol development and statistical analysis. The company is experienced in cardiac safety and efficacy testing in Phase I-IV and Thorough QT clinical trials. These services are supported by the company’s advanced data management system featuring the proprietary HolterGateway™ and CardioPortal™. Cardiocore’s U.S. headquarters is located in Bethesda, Maryland, its West Coast office is located in San Francisco, California, and its European subsidiary, Cardiocore Limited, is located in London, England. www.cardiocore.com